IL2 and systemic lupus erythematosus: Recent trials have suggested that calcineurin inhibitors including cyclosporine may be a potential option for SLE.[11] Cyclosporine binds to cyclophilin and inhibits calcineurin, thus inhibiting the production and release of interleukin-2 and subsequent interleukin-2-induced activation of resting T-lymphocytes.[12] Cyclosporine can also reduce proteinuria through the stabilization of the actin cytoskeleton in renal podocytes.